ZOLL Medical's (ZOLL) LifeVest Discussed at American Heart Association 2009 Science Session
More News related to ZOLL
- SAMU Brasilia Implements ZOLL AutoPulse
- Free PocketCPR iPhone Training App Available for February Heart Month from ZOLL
- ZOLL LifeVest Selected as One of the Top Five Innovative Medical Devices of 2009 by the Medical Device Network
- ZOLL Awarded Therapeutic Temperature Management Contract with HealthTrust Purchasing Group
- ZOLL Medical Corporation Announces First Quarter Results
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
ZOLL Medical Corporation (Nasdaq: ZOLL) announced that the LifeVest(R) wearable defibrillator was discussed in three separate scientific presentations at the American Heart Association 2009 Science Session in Orlando, Florida last week. The LifeVest presentations at this premier multidisciplinary international cardiovascular meeting are an important indication of increasing acceptance as a standard of care for patients with a temporary risk of sudden cardiac arrest.
The LifeVest wearable defibrillator is worn by patients at risk of SCA, providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest allows a patient's physician time to assess their long-term arrhythmic risk and make appropriate plans. The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient's heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.
"I am pleased at the robust scientific discussion regarding the LifeVest during AHA 2009 Scientific Sessions," stated Richard A. Packer, Chairman and Chief Executive Officer of ZOLL. "The research discussed in these lectures further demonstrates how the LifeVest is continuing to gain acceptance as a standard of care for an expanding number of patients at risk of sudden cardiac arrest."
[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
